Pharma Journalist -

Merck, known as MSD outside the United States and Canada, announced the presentation of results of a Phase 3 trial evaluating the efficacy and safety of BELSOMRA (suvorexant) C-IV for…
Read More...

Bicycle Therapeutics, a biotechnology company pioneering a new class of therapeutics based on its proprietary bicyclic peptide (Bicycle) product platform, announced a collaboration with…
Read More...

Verve Therapeutics announced its launch to discover and develop therapies that safely edit the adult human genome to permanently reduce a person’s risk of coronary artery disease, the…
Read More...

The European Commission has approved Dupixent (dupilumab) for use in adults and adolescents 12 years and older as an add-on maintenance treatment for severe asthma with type 2…
Read More...

Pfizer Inc. announced that the European Commission (EC) granted conditional marketing authorization for LORVIQUA (lorlatinib, available in the U.S., Canada and Japan under the brand…
Read More...

Sensei Biotherapeutics, Inc., a clinical-stage biopharmaceutical company developing precision immuno-oncology therapies, announced a clinical trial collaboration with AstraZeneca to…
Read More...

Ligand Pharmaceuticals Incorporated announces the acquisition of economic rights to SB206 from Novan, Inc. SB206 is a Phase 3 topical antiviral gel for the treatment of skin infections,…
Read More...

Xencor announced that the first patient has been dosed in XmAb23104-01 (DUET-3), a Phase 1 clinical study to evaluate the safety and tolerability of XmAb23104, a bispecific antibody…
Read More...

On May 3, the U.S. Food and Drug Administration approved Vyndaqel (tafamidis meglumine) and Vyndamax (tafamidis) capsules for the treatment of the heart disease (cardiomyopathy) caused…
Read More...

Skyhawk Therapeutics announced a strategic collaboration with Takeda Pharmaceutical Company Limited (Takeda) in which Skyhawk will use its SkySTAR technology platform to discover and…
Read More...